[1] T. J. Dougherty et al., “Photodynamic Therapy,” JNCI J. Natl. Cancer Inst., vol. 90, no. 12, Jun. 1998, doi: 10.1093/jnci/90.12.889.
[2] K. R. Weishaupt, C. J. Gomer, and T. J. Dougherty, “Identification of singlet oxygen as the cytotoxic agent in photo inactivation of a murine tumor,” Cancer Res., vol. 36, no. 7, 1976.
[3] P. Agostinis et al., “Photodynamic therapy of cancer: An update,” CA. Cancer J. Clin., 2011, doi: 10.3322/caac.20114.
[4] C. A. Morton et al., “European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen’s disease and basal cell carcinomas,” J. Eur. Acad. Dermatology Venereol., vol. 33, no. 12, Dec. 2019, doi: 10.1111/jdv.16017.
[5] A. Casas, “Clinical uses of 5-aminolaevulinic acid in photodynamic treatment and photodetection of cancer: A review,” Cancer Letters, vol. 490. 2020, doi: 10.1016/j.canlet.2020.06.008.
[6] D. van Straten, V. Mashayekhi, H. S. de Bruijn, S. Oliveira, and D. J. Robinson, “Oncologic photodynamic therapy: Basic principles, current clinical status and future directions,” Cancers, vol. 9, no. 2. 2017, doi: 10.3390/cancers9020019.
[7] B. Mansoori et al., “Photodynamic therapy for cancer: Role of natural products,” Photodiagnosis Photodyn. Ther., vol. 26, pp. 395–404, 2019, doi: 10.1016/j.pdpdt.2019.04.033.
[8] T. N. Chinembiri, L. H. Du Plessis, M. Gerber, J. H. Hamman, and J. Du Plessis, “Review of natural compounds for potential skin cancer treatment,” Molecules, vol. 19, no. 8. 2014, doi: 10.3390/molecules190811679.
[9] L. M. Baltazar, A. Ray, D. A. Santos, P. S. Cisalpino, A. J. Friedman, and J. D. Nosanchuk, “Antimicrobial photodynamic therapy: An effective alternative approach to control fungal infections,” Frontiers in Microbiology. 2015, doi: 10.3389/fmicb.2015.00202.
[10] M. R. Hamblin, “Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes,” Current Opinion in Microbiology. 2016, doi: 10.1016/j.mib.2016.06.008.
[11] P. Awasthi, A. Sharma, and M. Vatsal, “Spectroscopic, viscometric and computational binding study of 1 and 2 substituted anthraquinone analogs to be potential anti-cancer agents,” J. Mol. Struct., 2021, doi: 10.1016/j.molstruc.2020.129293.
[12] W. Tian, C. Wang, D. Li, and H. Hou, “Novel anthraquinone compounds as anticancer agents and their potential mechanism,” Future Med. Chem., vol. 12, no. 7, pp. 627–644, 2020, doi: 10.4155/fmc-2019-0322.
[13] W. Tian et al., “Novel Anthraquinone Compounds Induce Cancer Cell Death through Paraptosis,” ACS Med. Chem. Lett., 2019, doi: 10.1021/acsmedchemlett.8b00624.
[14] Y. Liu et al., “An autophagy-dependent cell death of MDA-MB-231 cells triggered by a novel Rhein derivative 4F,” Anticancer. Drugs, 2019, doi: 10.1097/CAD.0000000000000820.
[15] Z. Su et al., “A novel Rhein derivative: Activation of Rac1/NADPH pathway enhances sensitivity of nasopharyngeal carcinoma cells to radiotherapy,” Cell. Signal., 2019, doi: 10.1016/j.cellsig.2018.11.015.
[16] Y. T. Han, X. H. Chen, H. Gao, J. L. Ye, and C. B. Wang, “Physcion inhibits the metastatic potential of human colorectal cancer SW620 cells in vitro by suppressing the transcription factor SOX2,” Acta Pharmacol. Sin., 2016, doi: 10.1038/aps.2015.115.
[17] G. Shaghayegh et al., “Effects of damnacanthal and nordamnacanthal on proliferation, apoptosis, and migration of oral squamous cell carcinoma cells,” Asian Pacific J. Cancer Prev., 2017, doi: 10.22034/APJCP.2017.18.12.3333.
[18] J. A. García-Vilas, A. Pino-Ángeles, B. Martínez-Poveda, A. R. Quesada, and M. Á. Medina, “The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects,” Cancer Lett., 2017, doi: 10.1016/j.canlet.2016.10.037.
[19] R. A. Alderden, H. R. Mellor, S. Modok, T. W. Hambley, and R. Callaghan, “Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug,” Biochem. Pharmacol., 2006, doi: 10.1016/j.bcp.2005.12.039.
[20] N. B. Rumie Vittar et al., “Photochemotherapy using natural anthraquinones: Rubiadin and Soranjidiol sensitize human cancer cell to die by apoptosis,” Photodiagnosis Photodyn. Ther., 2014, doi: 10.1016/j.pdpdt.2014.02.002.
[21] A. P. Castano, T. N. Demidova, and M. R. Hamblin, “Mechanisms in photodynamic therapy: Part one - Photosensitizers, photochemistry and cellular localization,” Photodiagnosis and Photodynamic Therapy. 2004, doi: 10.1016/S1572-1000(05)00007-4.
[22] S. C. Núñez Montoya, L. R. Comini, B. Rumie Vittar, I. M. Fernández, V. A. Rivarola, and J. L. Cabrera, “Phototoxic effects of Heterophyllaea pustulata (Rubiaceae),” Toxicon, vol. 51, no. 8, pp. 1409–1415, 2008, doi: 10.1016/j.toxicon.2008.03.011.
[23] L. R. Comini, I. M. Fernandez, N. B. R. Vittar, S. C. Núñez Montoya, J. L. Cabrera, and V. A. Rivarola, “Photodynamic activity of anthraquinones isolated from Heterophyllaea pustulata Hook f. (Rubiaceae) on MCF-7c3 breast cancer cells,” Phytomedicine, 2011, doi: 10.1016/j.phymed.2011.05.008.
[24] L. R. Comini et al., “Parietin: an efficient photo-screening pigment in vivo with good photosensitizing and photodynamic antibacterial effects in vitro,” Photochem. Photobiol. Sci., 2017, doi: 10.1039/C6PP00334F.
[25] M. L. Mugas et al., “Photodynamic therapy of tumour cells mediated by the natural anthraquinone parietin and blue light,” J. Photochem. Photobiol. B Biol., 2021, doi: 10.1016/j.jphotobiol.2020.112089.
[26] S. Galli et al., “Characterization of a fibroblastoid mammary carcinoma cell line (LM2) originated from a mouse adenocarcinoma.,” Int. J. Oncol., 2000, doi: 10.3892/ijo.17.6.1259.
[27] F. Denizot and R. Lang, “Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability,” J. Immunol. Methods, 1986, doi: 10.1016/0022-1759(86)90368-6.
[28] G. Calvo et al., “Reversal of the Migratory and Invasive Phenotype of Ras-Transfected Mammary Cells by Photodynamic Therapy Treatment,” J. Cell. Biochem., 2017, doi: 10.1002/jcb.25657.
[29] P. Workman et al., “United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition),” British Journal of Cancer. 1998, doi: 10.1038/bjc.1998.1.
[30] E. Lopez-Tobar, V. Verebova, L. Blascakova, D. Jancura, G. Fabriciova, and S. Sanchez-Cortes, “Detection and aggregation of the antitumoral drug parietin in ethanol/water mixture and on plasmonic metal nanoparticles studied by surface-enhanced optical spectroscopy: Effect of pH and ethanol concentration,” Spectrochim. Acta - Part A Mol. Biomol. Spectrosc., vol. 159, pp. 134–140, 2016, doi: 10.1016/j.saa.2016.01.033.
[31] G. J. Peters, J. Van Dijk, J. C. Nadal, C. J. Van Groeningen, J. Lankelma, and H. M. Pinedo, “Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer,” In Vivo (Brooklyn)., 1987.
[32] T. Tang, L. Yin, J. Yang, and G. Shan, “Emodin, an anthraquinone derivative from Rheum officinale Baill, enhances cutaneous wound healing in rats,” Eur. J. Pharmacol., vol. 567, no. 3, 2007, doi: 10.1016/j.ejphar.2007.02.033.
[33] Y. L. Leu, T. L. Hwang, J. W. Hu, and J. Y. Fang, “Anthraquinones from Polygonum cuspidatum as tyrosinase inhibitors for dermal use,” Phyther. Res., vol. 22, no. 4, 2008, doi: 10.1002/ptr.2324.
[34] M. Adnan et al., “Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities,” Curr. Drug Targets, vol. 22, no. 5, 2020, doi: 10.2174/1389450121999201013154542.
[35] L. Helander, H. E. Krokan, A. Johnsson, O. A. Gederaas, and K. Plaetzer, “ Red versus blue light illumination in hexyl 5-aminolevulinate photodynamic therapy: the influence of light color and irradiance on the treatment outcome in vitro ,” J. Biomed. Opt., vol. 19, no. 8, 2014, doi: 10.1117/1.jbo.19.8.088002.
[36] Y. C. Kuo, C. M. Sun, J. C. Ou, and W. J. Tsai, “A tumor cell growth inhibitor from Polygonium hypoleucum Ohwi,” Life Sci., vol. 61, no. 23, 1997, doi: 10.1016/S0024-3205(97)00937-5.
[37] Y. C. Chen et al., “Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production,” Biochem. Pharmacol., vol. 64, no. 12, 2002, doi: 10.1016/S0006-2952(02)01386-2.
[38] J. Dimmer, Fotosensibilizadores fotodinámicos naturales y potenciales aplicaciones terapéuticas. Córdoba: Universidad Nacional de Córdoba, 2017.
[39] P. Shaul et al., “The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity,” ACS Med. Chem. Lett., vol. 4, no. 3, 2013, doi: 10.1021/ml3002852.
[40] M. M. Kleinpenning, T. Smits, M. H. A. Frunt, P. E. J. van Erp, P. C. M. van de Kerkhof, and R. M. J. P. Gerritsen, “Clinical and histological effects of blue light on normal skin,” Photodermatol. Photoimmunol. Photomed., 2010, doi: 10.1111/j.1600-0781.2009.00474.x.
[41] E. V. Maytin, U. Kaw, M. Ilyas, J. A. Mack, and B. Hu, “Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: A bilaterally controlled comparison study,” Photodiagnosis Photodyn. Ther., vol. 22, 2018, doi: 10.1016/j.pdpdt.2018.02.009.
[42] R. A. Akasov et al., “Photodynamic therapy of melanoma by blue-light photoactivation of flavin mononucleotide,” Sci. Rep., vol. 9, no. 1, 2019, doi: 10.1038/s41598-019-46115-w.
[43] C. D. Thomas, F. Poyer, P. Maillard, B. Chauvin, M. Lupu, and J. Mispelter, “Cellular density, a major factor involved in PDT cytotoxic responses: Study on three different lines of human retinoblastoma grafted on nude mice,” Photodiagnosis Photodyn. Ther., vol. 12, no. 2, 2015, doi: 10.1016/j.pdpdt.2015.01.002.
[44] R. Honegger, Mycobiont-photobiont interactions in adult thalli and in axenically resynthesized pre-thallus stages of Xanthoria parietina Teloschistales, lichenized Ascomycetes., vol. 38. Berlin: J. Cramer in Gebrüder Borntrae, 1990.
[45] S. C. Nuñez Montoya, A. M. Agnese, C. Pérez, I. N. Tiraboschi, and J. L. Cabrera, “Pharmacological and toxicological activity of Heterophyllaea pustulata anthraquinone extracts,” Phytomedicine, vol. 10, no. 6–7, pp. 569–574, 2003, doi: 10.1078/094471103322331854.
[46] S. C. Núñez Montoya, A. M. Agnese, and J. L. Cabrera, “Anthraquinone derivatives from Heterophyllaea pustulata,” J. Nat. Prod., vol. 69, no. 5, pp. 801–803, 2006, doi: 10.1021/np050181o.
[47] S. Kamaraju, J. Depke, J. Povletich, A. Currey, and E. Weil, “Cutaneous metastasis due to breast cancer in a patient with primary biliary cirrhosis: A case report,” Case Rep. Oncol., vol. 9, no. 3, 2016, doi: 10.1159/000452145.
[48] J. Sandby-Møller, T. Poulsen, and H. C. Wulf, “Epidermal Thickness at Different Body Sites: Relationship to Age, Gender, Pigmentation, Blood Content, Skin Type and Smoking Habits,” Acta Derm. Venereol., vol. 83, no. 6, 2003, doi: 10.1080/00015550310015419.